UPC Analytics
DEEN
Übersicht · Eingereicht: 8. Aug. 2025

UPC_CFI_722/2025

METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

NichtigkeitHauptnichtigkeitsklageMilan CDRevocationCase Closed
  • 2026-03-13outcomeName.otherrevocation_meritsRevocation Action

    The Milan Central Division ordered disposal of Neurocrine Biosciences' revocation action (R. 360 RoP) against EP 3 784 233 because the patent had been definitively and entirely revoked by the EPO Opposition Division, rendering the revocation action devoid of purpose. Neurocrine's conditional request (disposal only if Spruce undertook not to enforce divisional patents) was held outside R. 360 RoP. Spruce (claimant/respondent) was ordered to pay 80% of maximum recoverable costs (EUR 488,000) to Neurocrine; Neurocrine was reimbursed 60% of court fees (EUR 12,000).